Compare Franco-Nevada Corporation (FNV) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Franco-Nevada Corporation trades at $236.47 (market cap $45.36B), while GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B). The key difference: Franco-Nevada Corporation is the larger of the two by market cap, and Franco-Nevada Corporation pays the higher dividend (0.75%). Which is the better fit depends on your goals.
| FNV | GEHC | |
|---|---|---|
Market Cap | $45.36B | $30.93B |
Volume | 787,841 | 5,033,451 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $88.16 |
52-Week Low | $183.97 | $59.48 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $44.34B | $39.39B |
Dividend Yield | 0.75% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
